Skip to content
10-K

Annual Report

HAEMONETICS CORPORATION HAE

0000313143-25-000025

← back to feed
Filed
May 21, 2025 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2025 · May 16, 2025 48.04M sh
Long Term Debt FY 2025 · Mar 30, 2024 $797.56M
Cash And Equivalents FY 2025 · Mar 30, 2024 $178.8M
Current Liabilities FY 2025 · Mar 30, 2024 $300.38M
Current Assets FY 2025 · Mar 30, 2024 $768.9M
Total Assets FY 2025 · Mar 30, 2024 $2.2B
Shares Diluted FY 2025 · Apr 1, 2023 51.42M sh
Stock Repurchased FY 2025 · Apr 1, 2023 $75M
Capex restated FY 2025 · Apr 1, 2023 $191.33M
Operating Cash Flow FY 2025 · Apr 1, 2023 $273.06M
Eps Diluted FY 2025 · Apr 1, 2023 $2.24
Eps Basic FY 2025 · Apr 1, 2023 $2.27
Sga Expense FY 2025 · Apr 1, 2023 $376.68M
Rd Expense FY 2025 · Apr 1, 2023 $50.13M
Net Income FY 2025 · Apr 1, 2023 $115.4M
Operating Income FY 2025 · Apr 1, 2023 $156.03M
Gross Profit FY 2025 · Apr 1, 2023 $615.1M
Cost Of Revenue FY 2025 · Apr 1, 2023 $553.56M
Revenue FY 2025 · Apr 1, 2023 $1.17B
Stockholders Equity FY 2025 · Apr 2, 2022 $749.42M